Research programme: matrix metalloprotease inhibitors - Hebrew UniversityAlternative Names: Matrix metalloprotease inhibitors research programme - Hebrew University; Matrix metalloproteinase inhibitors research programme - Hebrew University; MMP inhibitors research programme - Hebrew University; Research programme: matrix metalloproteinase inhibitors - Hebrew University; Research programme: MMP inhibitors - Hebrew University
Latest Information Update: 23 Apr 2002
At a glance
- Originator Nonindustrial source
- Mechanism of Action Collagenase inhibitors; Metalloprotease inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 13 Mar 2000 New profile
- 13 Mar 2000 Preclinical development for Cancer in Israel (Unknown route)